Leah Croll, MD, Assistant Professor of Clinical Neurology at the Lewis Katz School of Medicine at Temple University, offered insight to NBC10 about Leqembi, which has been granted full approval by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease. The drug is indicated for those with mild cognitive impairment or the mild dementia stage of Alzheimer’s.
Important announcement concerning Temple Health and Keystone First. Our provider agreement with Keystone First is scheduled to end on July 31st. Click the link below to learn about your options for continuing care at Temple Health.
Learn More
800-TEMPLE-MED
Schedule Appointment
SEARCH TEMPLE HEALTH